Show simple item record

dc.contributor.authorOzberk, Victoria
dc.contributor.authorZaman, Mehfuz
dc.contributor.authorLangshaw, Emma
dc.contributor.authorEskandari, Sharareh
dc.contributor.authorCalcutt, Ainslie
dc.contributor.authorPowell, Jessica
dc.contributor.authorBatzloff, Michael R
dc.contributor.authorDietrich, Jes
dc.contributor.authorPandey, Manisha
dc.contributor.authorGood, Michael F
dc.description.abstractVictoria Ozberk Streptococcus pyogenes (Group A Streptococcus; GAS) infections and their sequelae are responsible for significant morbidity and mortality worldwide. A vaccine that can prevent GAS infection at the primary sites of infection is urgently needed to block the onset of potentially life threatening GAS-associated diseases. We demonstrated that intranasal administration of a liposomal delivery system, incorporating GAS peptide antigens, J8 and S2, protects against upper respiratory tract (URT) infection with wild-type and hypervirulent GAS strains. Addition of an immunostimulatory glycolipid to the mucosally active liposomal vaccine significantly enhanced vaccine efficacy to protect at both mucosal and systemic compartments of immunity. We show that secretory IgA is not necessary in vaccine-mediated protection against URT GAS infection but that a vaccine-specific IL-17A response is associated with protection. Furthermore, we show that prime-pull immunisation with J8-DT and K4S2- DT formulated with another novel liposomal delivery system promotes high and sustained antibody levels in the airway mucosa and in the serum. The same vaccine also leads to the establishment of cellular immunity and protection against skin and URT hypervirulent GAS infections. In conclusion, the findings reported here represent a significant advancement in overcoming many obstacles impeding the development of GAS vaccines to prevent infection at mucosal and systemic sites.
dc.publisherThe American Journal of Tropical Medicine and Hygiene
dc.relation.ispartofconferencename68th Annual Meeting of the American-Society-for-Tropical-Medicine-and-Hygiene (ASTMH)
dc.relation.ispartofconferencetitleAmerican Journal of Tropical Medicine and Hygiene
dc.relation.ispartoflocationNational Harbor, MD
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsPublic, Environmental & Occupational Health
dc.subject.keywordsTropical Medicine
dc.titleDesign and evaluation of novel liposome-based peptide vaccines for improved efficacy against group a streptococcal infections of mucosa and skin
dc.typeConference output
dc.type.descriptionE3 - Conferences (Extract Paper)
dcterms.bibliographicCitationOzberk, V; Zaman, M; Langshaw, E; Eskandari, S; Calcutt, A; Powell, J; Batzloff, MR; Dietrich, J; Pandey, M; Good, MF, Design and evaluation of novel liposome-based peptide vaccines for improved efficacy against group a streptococcal infections of mucosa and skin, American Journal of Tropical Medicine and Hygiene, 2019, 101 (5_Suppl), pp. 146-146
gro.hasfulltextNo Full Text
gro.griffith.authorPandey, Manisha
gro.griffith.authorZaman, Mehfuz
gro.griffith.authorEskandari, Sherry
gro.griffith.authorOzberk, Victoria
gro.griffith.authorPowell, Benjamin
gro.griffith.authorGood, Michael F.
gro.griffith.authorCalcutt, Ainslie M.
gro.griffith.authorBatzloff, Michael R.
gro.griffith.authorLangshaw, Emma

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record